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Available online 8 June 2019Nonepileptic seizures (NES, psychogenic NES-PNES) are associated with significant morbidities. We evaluated
the morbidities and mortality in a national group of children, adolescent, and adult patients before and after a
first diagnosis of PNES.
Methods: From the Danish National Patient Registry (1998–2013), we identified 1057 people of all ages with a
diagnosis of NES andmatched themwith 2113 control individuals by age, gender, and geography. Comorbidities
were calculated three years before and after diagnoses.
Results: Patients with PNES showed increased comorbidities 3 years before and after diagnosis in almost all the
diagnostic domains.
The strongest associations were identified with other neurological diseases (after diagnosis, Hazard Ratio (HR):
38.63; 95% Confidence Interval (CI): 21.58–69.13; P b 0.001), abnormal clinical and laboratory findings (HR:
46.59; 95 CI: 27.30–79.52; P b 0.001), other health-related factors (HR: 12.83; 95%CI: 8.45–19.46; P b 0.001),
and psychiatric comorbidities (HR: 15.45; 95% CI: 9.81–24.33). Epilepsy was identified in 8% of the patients
with PNES. We found especially frequent comorbidity involving overweight, depression, anxiety, dissociative
somatoform condition, other convulsions, lipothymias, reports of pain and other symptoms in several organ sys-
tems, and several reports ofminimal traumas to the head, trunk, and extremities.Mortalitywas higher in patients
with NES than in controls (HR: 3.21; 95% CI: 1.92–5.34; P b 0.001).
Conclusion: Morbidity is more frequent in several domains, including neurological, psychiatric, and other dis-
eases, before and after a diagnosis of NES. Mortality is significantly higher in patients with PNES as compared
to controls.








Controlled studyEpilepsy affects approximately 1% of children and adults, and is asso-
ciatedwith significant comorbidities andmortality, and personal, famil-
iar, and societal consequences [1]. Episodes with transient behavioral
abnormalities or changes in consciousness may be different in nature,
e.g., as if they are different events neurological, cardiovascular, or psy-
chological. Diagnosing epilepsy may be difficult due to the complex na-
ture of the disorders, the occurrences of seizures, the timing, and reportsellberg (JK): creation, initiation,
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d interpretation of the data, the
for publication.
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. This is an open access article underfrom patients and witnesses. Other causes of ictal events include epi-
sodes of nonepileptic seizures (NES), e.g., other pathological conditions
(cardiac and vasovagal disorders) and other neurological (e.g., cata-
plexy in narcolepsy) and malingering or psychogenically induced sei-
zures (psychogenic NES [PNES]).
Diagnosing PNES is challenging, which, due to the potential risk of in-
correct diagnosis, should depend on positive criteria, includingwitnessed
of clinical episodes and/or long-term video-electroencephalographic
(vEEG) recordings [2–4]. Despite the application of these criteria, there
is still a degree of uncertainty about diagnoses.
The cause and etiologies of PNES include complexmechanisms, such
as constitutional, psychological, social, familiar, and other complex
pathways. Patients with PNES may suffer from several other comorbid-
ities. Previous studies have focused on psychopathology and comorbid
psychiatric disorders which occur in a significant proportion of patient
with PNES [5–11], and PNES may occur in patients with epilepsy [5,7,
12,13]. A systematic approach to the evaluation of PNES with respect




N % N %
Total 1057 2113
Age (years)
0–10 240 22.7 479 22.7
11–20 246 23.3 492 23.3
21–30 167 15.8 334 15.8
31–40 120 11.4 240 11.4
41–50 89 8.4 178 8.4
51–60 82 7.8 164 7.8
61–70 63 6.0 126 6.0
71–80 32 3.0 64 3.0
N80 18 1.7 36 1.7
Gender
Male 325 30.7 650 30.8
Female 732 69.3 1463 69.2
Marital status
Married 630 59.6 1259 59.6
Not married 427 40.4 854 40.4
230 P. Jennum et al. / Epilepsy & Behavior 96 (2019) 229–233subjects. There is currently very limited long-term follow-up data re-
garding morbidities and mortality in patient with PNES.
In Denmark, the diagnosis of PNES depends on careful diagnostic
procedures, including several nonictal and ictal vEEGs. In this study,
we aim to present the results of the comparison of all identified national
cases of PNES cases with matched controls regarding comorbidities and
mortality.
1. Methods
1.1. Patients and controls
The methods used in this study follow those of two previous studies
[14,15]. Our current study is based on reports from all Danish clinics and
hospitals registered in the Danish National Patient Registry (NPR). The
NPR is a time-based national database of administrative information, di-
agnoses, and diagnostic and treatment procedures that uses several in-
ternational classification systems, including the International
Classification of Disorders (ICD-10). This is possible because all Danes
are registered using social security codes, enabling the collection of
linked data, including health information. Data on the time and type
of health contacts cover those related to the hospital sector, including
diagnostic and treatment procedures at the time of diagnosis. Thus, it
is a complete national sample containing the dates of contact and diag-
noses of all patients.
Since April 1968, all Danish citizens have been assigned a unique
identifier (Central Personal Registration [CPR] number), which is re-
corded in the Danish Civil Registration System along with information
about place of birth and residence and vital and marital status [16].
Denmark includes approximately 5.8 mill citizens; almost all citizens
have a patient contact with the healthcare system and are consequently
registered in the NPR.
Since the NPR contains details of all patient contacts, the data may be
representative of all patients in Denmark who have received a diagnosis
of (psychogenic) NES (DR568G, DF445, or DF449) in the secondary sector
and in public and private hospitals. The year of diagnosis was defined as
the first time a patient was registered with the diagnosis of PNES (index
date) in the NPR between 2011 and 2016 (calendar year). Patients were
followed until death, emigration, or 31st December 2016.
We identified all patients when they received their first diagnosis.
We set up a control group that was randomly selected but matched by
age, gender, and geography (county) at the time of the initial diagnosis.
The controls had no diagnosis of NES but may have suffered from other
diseases. Each patient was matched with four controls. Information
about health was obtained from the NPR, which we used to estimate
the totalmorbidity andmortality of the cohort. The studywas approved
by the Danish Data Protection Agency. The study was register-based so
no approval from the ethics committee was needed.
1.2. Comorbidity and mortality after diagnosis (postindex)
A postindex measure of patient comorbidity in the first three years
before and after the initial PNES diagnosis was calculated for the cohort.
The index of PNES diagnosis was not included in the calculation of co-
morbidity, but subsequent contacts due to NES were included in the
analysis, as were those due to other neurological disorders.
Pre- and postindex comorbidity for the 21 WHO chapters was ana-
lyzed by examining the odds ratios (conditional logit model). A more
detailed analysis of the ICD-10 diagnoses that typically occur in patients
with PNES is provided. The diagnoses were calculated based on the first
three digits, and only those occurring in at least 3% of the patient or con-
trol groupwere included in this analysis. Logistic regressionwas used to
examine the included diagnoses, controlling for the level of parental
education.
We also evaluated annual all-cause mortality after the initial PNES
diagnosis.Statistical analyses were performed using SAS 9.1.3 (SAS, Inc., Cary,
NC, USA).
2. Results
One thousand fifty seven patients with PNES were identified and
compared with 2113matched controls. Forty six percent were children
(0–20 years old) (Table 1). The number of identified patients per year
was about the same for the period (2011: 81; 2012: 185; 2013: 206;
2014: 180; 2015: 221 2016: 184). Four hundred fifty five patients
with PNES and 912 controls were identified who had prediagnosis in-
formation, and 472 patients with PNES and corresponding 974 controls
were selected who had postdiagnosis information for at least three
years, estimated from the date of diagnosis. All patients showed signif-
icantly higher frequencies in several disease areas, as documented in
the 21 chapters of the WHO classification before, and particularly
after, diagnosis (Table 2). The analysis of the separate diagnoses for dis-
eases that occurred inmore than 3% of patients is presented in Table 3. It
is notable that there is a significant and overwhelming number of pa-
tientswith PNES: both before and after diagnoses of overweight, psychi-
atric diseases, but also following a diagnosis of other types of convulsion
(not recorded as psychogenic or epileptic), lipothymias, and other ab-
normal movements are reported. Moreover, patients with PNES report
several additional somatoform symptoms from the head, trunk, extrem-
ities, and pain complaints. Patients with PNES have significantly more
contact with health services for minor traumas affecting all body
parts. As we only included occurrences with a frequency of more than
3% for each diagnosis, almost none of these reports were identified in
the controls (Table 4).
Mortality was greater in patients with PNES than in controls (HR:
3.21; 95% CI: 1.92–5.34; P b 0.001) (Fig. 1).
3. Discussion
We prospectively evaluated the comorbidity rates in childhood, ad-
olescence, and adult PNES in a national sample with matched controls.
The study made several important novel findings: 1) patients with
PNES showed elevated comorbidities in several of the 21 WHO disease
groups; 2) the associations included overweight, psychiatric diseases,
other types of nonepileptic convulsion, lipothymias, abnormal move-
ments, somatoform symptoms, pain, and minor traumas; and 3) the
mortality rate was significant and 3 times higher in patients with
PNES this small population. Thus, PNES is associated with a wide
range of comorbidities but is dominated by unspecific health contacts
Table 2
Comorbidities (WHO 21 Chapters) of patients three years before their initial NES diagnosis.













Odds ratio Lower 5% Upper 90% P
Infectious and parasitic diseases 32 41 6.8 4.3 1.62 1.00 2.62 0.051
Neoplasms 25 42 5.3 4.5 1.21 0.72 2.02 0.473
Blood and immunological diseases 12 11 2.5 1.2 2.18 0.96 4.94 0.062
Endocrine, nutritional and metabolic diseases 73 52 15.5 5.5 3.15 2.15 4.61 b0.001
Mental and psychiatric disorders 142 30 30.1 3.2 12.95 8.18 20.49 b0.001
Nervous system disorders 193 22 40.9 2.3 33.90 18.45 62.29 b0.001
Diseases of the eye and adnexa 35 28 7.4 3.0 2.83 1.65 4.87 b0.001
Ear, nose, and throat diseases 24 12 5.1 1.3 4.24 2.07 8.68 b0.001
Circulatory/cardiovascular diseases 79 56 16.7 5.9 3.83 2.54 5.78 b0.001
Respiratory diseases 64 51 13.6 5.4 2.75 1.86 4.07 b0.001
Gastrointestinal diseases 62 70 13.1 7.4 1.92 1.33 2.78 0.001
Skin and subcutaneous tissue diseases 24 25 5.1 2.7 2.02 1.13 3.63 0.018
Musculoskeletal system and connective tissue diseases 103 116 21.8 12.3 2.08 1.53 2.82 b0.001
Genito-urinary diseases 53 58 11.2 6.1 1.94 1.31 2.88 0.001
Pregnancy, childbirth, and puerperium 29 60 6.1 6.4 0.95 0.57 1.61 0.860
Certain conditions originating in the perinatal period 24 43 5.1 4.6 1.20 0.63 2.27 0.584
Congenital malformations, deformations, and chromosomal abnormalities 28 19 5.9 2.0 3.04 1.68 5.50 b0.001
Abnormal clinical and laboratory findings 286 115 60.6 12.2 9.50 7.03 12.84 b0.001
Injury, poisoning, and certain other external causes 223 223 47.3 23.6 3.30 2.54 4.29 b0.001
External causes of morbidity and mortality 77 125 16.3 13.2 6.10 2.07 17.93 0.001
Other factors influencing health status and contact with health services 428 517 90.7 54.8 9.79 6.70 14.31 b0.001
Bold values statistically significant at P b 0.01.
231P. Jennum et al. / Epilepsy & Behavior 96 (2019) 229–233due mostly to psychiatric, nonspecific symptoms, and somatoform
complaints.
By using a national dataset in which all health contacts are recorded,
we found a striking feature of PNES in this study whereby the disorder
was associated with more disease consequences in several disease do-
mains. Psychogenic NES comorbidities were observed before the initial
diagnoses. Increased morbidity with long delays are noted in many
other diseases and conditions [17].
We found that PNES is associatedwith elevated rates ofmetabolic dis-
ease (overweight, diabetes type II, and hypercholesterolemia), which
makes it possible that PNES is linked to poor lifestyles and sedentary be-
havior, although no data are currently available to support this inference.Table 3






Infectious and parasitic diseases 51 38
Neoplasms 32 54
Blood and immunological diseases 22 14
Endocrine, nutritional, and metabolic diseases 75 67
Mental and psychiatric disorders 168 29
Nervous system disorders 241 36
Diseases of the eye and adnexa 44 40
Ear, nose, and throat diseases 23 20
Circulatory/cardiovascular diseases 80 57
Respiratory diseases 83 71
Gastrointestinal diseases 102 89
Skin and subcutaneous tissue diseases 39 32
Musculoskeletal system and connective tissue diseases 111 132
Genito-urinary diseases 83 86
Pregnancy, childbirth, and puerperium 29 77
Certain conditions originating in the perinatal period – –
Congenital malformations, deformations, and chromosomal abnormalities 19 18
Abnormal clinical and laboratory findings 412 139
Injury, poisoning, and certain other external causes 219 244
External causes of morbidity and mortality 7 15
Other factors influencing health status and contact with health services 420 473
Bold values statistically significant at P b 0.01.The strongest and most important finding in this study is the raised
prevalence of comorbidities involving psychiatric diseases (depression,
anxiety) and in dissociative and somatoform conditions. Case-based ob-
servations have highlighted the high frequency of specific psychological
profiles [5,18–21], and the high rates of depression, anxiety, and
somatoform conditions [18,22,23]. Somatoform patterns are also evident
in this study as more patients showed a greater number of contacts with
the healthcare system due to lipothymias, abnormal nonepileptic move-
ments, symptoms of multiple organ system and minor traumas. Patients
with epilepsy suffer from high rates of traumas and falls, although only
one study has identified a higher risk of injury [24]. The higher rate of ep-









Odds ratio Lower 5% Upper 90% P
10.8 4.0 3.08 1.95 4.88 b0.001
6.8 5.7 1.22 0.76 1.97 0.409
4.7 1.5 3.14 1.61 6.14 0.001
15.9 7.1 2.52 1.76 3.60 b0.001
35.6 3.1 15.45 9.81 24.33 b0.001
51.1 3.8 38.63 21.58 69.13 b0.001
9.3 4.2 2.40 1.52 3.80 b0.001
4.9 2.1 2.44 1.31 4.56 0.005
17.0 6.0 4.13 2.70 6.31 b0.001
17.6 7.5 2.75 1.93 3.92 b0.001
21.6 9.4 2.75 1.99 3.79 b0.001
8.3 3.4 2.52 1.56 4.06 b0.001
23.5 14.0 1.93 1.44 2.57 b0.001
17.6 9.1 2.23 1.59 3.13 b0.001
6.1 8.2 0.69 0.42 1.12 0.132
4.0 1.9 2.11 1.11 4.02 0.023
87.3 14.7 46.59 27.30 79.52 b0.001
46.4 25.9 2.55 2.00 3.24 b0.001
1.5 1.6 0.92 0.35 2.44 0.870
89.0 50.1 12.83 8.46 19.46 b0.001
Table 4
Comorbidities on selected diagnoses grouped into major symptoms or groups. All identified by occurrence of at least 3% of each diagnose.
Disease group Before After
PNES, N (%) Control, N (%) NES, N (%) Control, All N
Total N Total 455 912 472 974
Overweight and metabolic diseases 7 (1.5) 0 13 (2.8) 0
Depression, anxiety, and OCD 10 (2.2) 0 12 (2.5) 0
Dissociate and somatoform conditions 51 (11.2) 0 67 (12) 0
Epilepsy, including status epilepticus 36 (7.9) 0 42 (8.9) 0
Lipothymias 18 (3.9) 15 (7.2) 0
Unclassified convulsions 18 (3.9) 0 79 (16.3) 0
Other abnormal movements 16 (3.5) 12 (2.5) 0
Migraine, Horton headache, other chronic headaches 8 (1.8) 0 9 (1.9) 0
Unclassified CNS symptoms 18 (3.9) 0 29 (6.1) 0
Cardiovascular, bronchitis, and asthma 20 (4.8) 0 21 (4.4) 0
Symptoms from abdominal or urogenital system without specific somatic diagnosis 16 (3.5) 4 (0.4) 30 (6.8) 5 (0.5)
Rheumatism, pain 19 (4.2) 0 26 (5.5) 0
Lesion to the thorax, abdomen, or extremities 60 (13.6) 0 51 (10.8) 0
232 P. Jennum et al. / Epilepsy & Behavior 96 (2019) 229–233and vice versa [25,26]. Patients with PNES aremore likely not only to suf-
fer from personal problems but also to have a lower quality of life [5,27].
The multiple contacts with the healthcare system, the lower educational
level and poorer job adherence increase total welfare costs [28,29].
As the aim of the study was to identify the total health-related co-
morbidities of PNES, we included all the cases in the national sample
with a first diagnosis of PNES but did not consider the criteria for any
other verification of the diagnoses. A diagnosis of PNES in Denmark gen-
erally requires an extensive evaluation based on clinical history, several
EEGs, and ictal vEEG. The diagnosis is generally sensitive to misdiagno-
ses and careful evaluation of patients is needed, especially to avoid that
of a different physiological/pathological PNES. In this study, we primar-
ily aimed to evaluate the pattern of comorbidity, but not the underlying
causes involving constitutional, familiar, educational, psychological,
psychiatric, somatic, and social factors [5,30,31]. A number of interven-
tions for PNES have been proposed [32,33], including those involving
psychological management, but we have not evaluated the effect ofFig. 1.Mortalitthese factors during the course of the disease in this population because
it is too small to do so adequately.
We found a higher mortality rate in this small population of patients
with PNES than in controls. Several factors are responsible for the ele-
vatedmortality rates found in childhood, adolescent, and adult epilepsy
[1,34], including seizure severity, underlying diseases, medication, co-
morbidities, and life-style factors [35–37]. A previous study also re-
ported greater mortality in PNES [38]. The effect was relatively strong,
with an HR greater than 3, but the cause and etiology of the mortality
effect cannot be determined from this study, beyond being able to es-
tablish that the patients have higher rates of epilepsy, several comorbid-
ities, medication use (data not shown), and are likely to have a more
sedative lifestyle. Epilepsy cannot explain the higher mortality rates in
the study as relatively few patients suffered from epileptic seizures.
The strength of our study is that we were able to identify all patients
with a diagnosis of PNES and to establish controls based on demographic
variables. In this study, the control group was selected based on age,y in PNES.
233P. Jennum et al. / Epilepsy & Behavior 96 (2019) 229–233gender, and geography (the latter to allow adjustment for social factors);
it was not selected to be a group of healthy subjects. If we had compared
patients with PNES with healthy members of the general population, the
differences and morbidities would have been more pronounced.
The study is limited by our inability to evaluate the criteria bywhich
the individual diagnoses were made; e.g., whether they were based on
clinical information or if episodeswere classified based on ictal vEEG re-
cordings. We selected only four controls per patient to reduce the vari-
ance among controls. To be included as a control, they could not have a
diagnosis of PNES, or be suspected of having PNES, although they may
well have had other disorders.We did not control for parental social fac-
tors. It is likely that thiswould be of relevance since PNES is probably in-
fluenced by social rank [39]. However, the data here were insufficiently
complete to enable the familiar analysis that would ideally be required.
In conclusion, the current study found that PNES was associated with
significantly more numerous health-related consequences, and that the
morbidities extended to several comorbidities other than brain diseases.
Healthcare professionals should be aware of the possibilities for detecting,
diagnosing, andmanaging PNES and epilepsy, and should ensure that pa-
tients receive adequate information about their disorders. Future research
should evaluate the importance of thesefindings includingunderstanding
the etiology and importance for management of PNES.
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